FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895721027> ?p ?o ?g. }

• W2895721027 endingPage "398" @default.
• W2895721027 startingPage "385" @default.
• W2895721027 abstract "CD40 ligand (TNFSF5/CD154/CD40L), a member of the tumor necrosis factor (TNF) superfamily is a key regulator of the immune system. The cognate receptor CD40 (TNFRSF5) is expressed broadly on antigen-presenting cells and many tumor types, and has emerged as an attractive target for immunologic cancer treatment. Most of the CD40 targeting drugs in clinical development are antibodies which display some disadvantages: their activity typically depends on Fcγ receptor-mediated crosslinking, and depletion of CD40-expressing immune cells by antibody-dependent cellular cytotoxicity compromises an efficient antitumor response. To overcome the inadequacies of antibodies, we have developed the hexavalent receptor agonist (HERA) Technology. HERA compounds are fusion proteins composed of 3 receptor binding domains in a single chain arrangement, linked to an Fc-silenced human IgG1 thereby generating a hexavalent molecule. HERA-CD40L provides efficient receptor agonism on CD40-expressing cells and, importantly, does not require FcγR-mediated crosslinking. Strong activation of NFκB signaling was observed upon treatment of B cells with HERA-CD40L. Monocyte treatment with HERA-CD40L promoted differentiation towards the M1 spectrum and repolarization of M2 spectrum macrophages towards the M1 spectrum phenotype. Treatment of in vitro co-cultures of T and B cells with HERA-CD40L-triggered robust antitumor activation of T cells, which depended upon direct interaction with B cells. In contrast, bivalent anti-CD40 antibodies and trivalent soluble CD40L displayed weak activity which critically depended on crosslinking. In vivo, a murine surrogate of HERA-CD40L-stimulated clonal expansion of OT-I-specific murine CD8 T cells and showed single agent antitumor activity in the CD40 syngeneic MC38-CEA mouse model of colorectal cancer, suggesting an involvement of the immune system in controlling tumor growth. We conclude that HERA-CD40L is able to establish robust antitumor immune responses both in vitro and in vivo." @default.
• W2895721027 created "2018-10-12" @default.
• W2895721027 creator A5013217770 @default.
• W2895721027 creator A5024872255 @default.
• W2895721027 creator A5028313527 @default.
• W2895721027 creator A5037806609 @default.
• W2895721027 creator A5052689205 @default.
• W2895721027 creator A5053232413 @default.
• W2895721027 creator A5071167810 @default.
• W2895721027 creator A5072237585 @default.
• W2895721027 creator A5079673431 @default.
• W2895721027 creator A5087666105 @default.
• W2895721027 creator A5089695326 @default.
• W2895721027 date "2018-11-01" @default.
• W2895721027 modified "2023-09-23" @default.
• W2895721027 title "The Hexavalent CD40 Agonist HERA-CD40L Induces T-Cell–mediated Antitumor Immune Response Through Activation of Antigen-presenting Cells" @default.
• W2895721027 cites W1489651318 @default.
• W2895721027 cites W1497698149 @default.
• W2895721027 cites W1518095394 @default.
• W2895721027 cites W1621322786 @default.
• W2895721027 cites W1875866108 @default.
• W2895721027 cites W1895971170 @default.
• W2895721027 cites W1898064153 @default.
• W2895721027 cites W1976857510 @default.
• W2895721027 cites W1981505729 @default.
• W2895721027 cites W1982861708 @default.
• W2895721027 cites W1986383624 @default.
• W2895721027 cites W1986799159 @default.
• W2895721027 cites W1993160173 @default.
• W2895721027 cites W1996603186 @default.
• W2895721027 cites W2004399826 @default.
• W2895721027 cites W2012705266 @default.
• W2895721027 cites W2015788325 @default.
• W2895721027 cites W2021967439 @default.
• W2895721027 cites W2041590173 @default.
• W2895721027 cites W2043991982 @default.
• W2895721027 cites W2053248202 @default.
• W2895721027 cites W2059485644 @default.
• W2895721027 cites W2065743975 @default.
• W2895721027 cites W2070373836 @default.
• W2895721027 cites W2073034575 @default.
• W2895721027 cites W2089515210 @default.
• W2895721027 cites W2109000663 @default.
• W2895721027 cites W2115373139 @default.
• W2895721027 cites W2129708967 @default.
• W2895721027 cites W2132537022 @default.
• W2895721027 cites W2134940917 @default.
• W2895721027 cites W2136107817 @default.
• W2895721027 cites W2136765597 @default.
• W2895721027 cites W2148165529 @default.
• W2895721027 cites W2151365509 @default.
• W2895721027 cites W2161870927 @default.
• W2895721027 cites W2166566481 @default.
• W2895721027 cites W2265604742 @default.
• W2895721027 cites W2274841994 @default.
• W2895721027 cites W2295620064 @default.
• W2895721027 cites W2404465151 @default.
• W2895721027 cites W2411733041 @default.
• W2895721027 cites W2510721083 @default.
• W2895721027 cites W2514449559 @default.
• W2895721027 cites W2566211375 @default.
• W2895721027 cites W2567501064 @default.
• W2895721027 cites W2580706718 @default.
• W2895721027 cites W2594615455 @default.
• W2895721027 cites W2611196568 @default.
• W2895721027 cites W4210637293 @default.
• W2895721027 doi "https://doi.org/10.1097/cji.0000000000000246" @default.
• W2895721027 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30273198" @default.
• W2895721027 hasPublicationYear "2018" @default.
• W2895721027 type Work @default.
• W2895721027 sameAs 2895721027 @default.
• W2895721027 citedByCount "16" @default.
• W2895721027 countsByYear W28957210272019 @default.
• W2895721027 countsByYear W28957210272020 @default.
• W2895721027 countsByYear W28957210272021 @default.
• W2895721027 countsByYear W28957210272022 @default.
• W2895721027 countsByYear W28957210272023 @default.
• W2895721027 crossrefType "journal-article" @default.
• W2895721027 hasAuthorship W2895721027A5013217770 @default.
• W2895721027 hasAuthorship W2895721027A5024872255 @default.
• W2895721027 hasAuthorship W2895721027A5028313527 @default.
• W2895721027 hasAuthorship W2895721027A5037806609 @default.
• W2895721027 hasAuthorship W2895721027A5052689205 @default.
• W2895721027 hasAuthorship W2895721027A5053232413 @default.
• W2895721027 hasAuthorship W2895721027A5071167810 @default.
• W2895721027 hasAuthorship W2895721027A5072237585 @default.
• W2895721027 hasAuthorship W2895721027A5079673431 @default.
• W2895721027 hasAuthorship W2895721027A5087666105 @default.
• W2895721027 hasAuthorship W2895721027A5089695326 @default.
• W2895721027 hasConcept C154317977 @default.
• W2895721027 hasConcept C159654299 @default.
• W2895721027 hasConcept C17991360 @default.
• W2895721027 hasConcept C185592680 @default.
• W2895721027 hasConcept C202751555 @default.
• W2895721027 hasConcept C203014093 @default.
• W2895721027 hasConcept C39347974 @default.
• W2895721027 hasConcept C55493867 @default.
• W2895721027 hasConcept C86803240 @default.

• next